# Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

> **NCT03533101** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 30 (actual)

## Conditions studied

- Cytokine Release Syndrome
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03533101
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-25
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-06-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533101, "Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03533101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*